The FDA Advisory Panel's decision on rt-PA

Area of Science:

• Cardiology
• Pharmacology
• Medical Devices

Background:

• Recombinant tissue plasminogen activator (rt-PA) is a thrombolytic agent.
• Acute myocardial infarction (heart attack) treatment is a critical area of medical research.
• The FDA's Cardio-renal Advisory Panel reviewed rt-PA for heart attack treatment.

Purpose of the Study:

• To address dissatisfaction with the FDA panel's recommendation to delay rt-PA approval.
• To evaluate the clinical benefit and safety data for rt-PA in treating acute myocardial infarction.
• To compare rt-PA with streptokinase regarding efficacy, safety, and cost.

Main Methods:

• Review of data submitted to the FDA regarding rt-PA's molecular form, dosage, and duration of therapy.
• Analysis of comparative claims between rt-PA and streptokinase.
• Consideration of rt-PA's association with rethrombosis and cost.

Main Results:

• The FDA panel recommended delaying rt-PA approval due to inadequate data.
• Questions exist regarding rt-PA's claimed safety (bleeding) and efficacy compared to streptokinase.
• rt-PA use is associated with higher rethrombosis rates and significantly greater cost.

Conclusions:

• Further data is required to establish the clinical benefit and safety of specific rt-PA regimens.
• The comparative advantages of rt-PA over streptokinase require further investigation.
• Cost-effectiveness and rethrombosis risks are important considerations for rt-PA adoption.